XML 24 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value of Financial Instruments (Tables)
6 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value
The following table summarizes the valuation of the Company’s remaining assets and liabilities measured at fair value on a recurring basis at December 31, 2019:

 
Total
 
Quoted
prices in
active
markets
(Level 1)
 
Significant
other
observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
 
(in thousands)
Assets:
 
 
 
 
 
 
 
Deferred compensation plan investments, current and non-current portion
$
28,839

 
$
28,839

 
$

 
$

Forward foreign currency exchange contracts
125

 

 
125

 

Total assets at fair value
$
28,964

 
$
28,839

 
$
125

 
$

Liabilities:
 
 
 
 
 
 
 
Deferred compensation plan investments, current and non-current portion
$
28,839

 
$
28,839

 
$

 
$

Forward foreign currency exchange contracts
320

 

 
320

 

Interest rate swap agreement
3,627

 

 
3,627

 

Liability for contingent consideration
45,043

 

 

 
45,043

Total liabilities at fair value
$
77,829

 
$
28,839

 
$
3,947

 
$
45,043


The following table summarizes the valuation of the Company’s remaining assets and liabilities measured at fair value on a recurring basis at June 30, 2019:

 
Total
 
Quoted
prices in
active
markets
(Level 1)
 
Significant
other
observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
 
(in thousands)
Assets:
 
 
 
 
 
 
 
Deferred compensation plan investments, current and non-current portion
$
25,787

 
$
25,787

 
$

 
$

Forward foreign currency exchange contracts
165

 

 
165

 

Total assets at fair value
$
25,952

 
$
25,787

 
$
165

 
$

Liabilities:
 
 
 
 
 
 
 
Deferred compensation plan investments, current and non-current portion
$
25,787

 
$
25,787

 
$

 
$

Forward foreign currency exchange contracts
168

 

 
168

 

Interest rate swap agreement
3,504

 

 
3,504

 

Liability for contingent consideration
77,925

 

 

 
77,925

Total liabilities at fair value
$
107,384

 
$
25,787

 
$
3,672

 
$
77,925


Schedule of Changes in Fair Value of Contingent Considerations The table below provides a summary of the changes in fair value of the Company's contingent considerations for the Intelisys earnout, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the quarter ended December 31, 2019.
 
Quarter ended December 31, 2019
Six months ended December 31, 2019
 
Worldwide Communications & Services Segment
 
(in thousands)
Fair value at beginning of period
$
80,397

 
$
77,925

Payments
(38,531
)
 
(38,531
)
Change in fair value of contingent consideration
3,176

 
5,649

Fair value at end of period
$
45,043

 
$
45,043



The table below provides a summary of the changes in fair value of the Company’s contingent considerations (Level 3) for the Network1 and Intelisys earnouts for the quarter and six months ended December 31, 2018.

 
Quarter ended December 31, 2018
 
Six months ended December 31, 2018
 
Worldwide Communications & Services Segment
 
(in thousands)
Fair value at beginning of period
$
80,173

 
$
108,233

Payments
(10,813
)
 
(43,060
)
Change in fair value of contingent consideration
1,850

 
6,434

Foreign currency translation adjustment
676

 
279

Fair value at end of period
$
71,886

 
$
71,886


Valuation techniques and significant observable inputs used in recurring Level 3 fair value measurements for our contingent consideration liability related to Intelisys at December 31, 2019 and June 30, 2019 were as follows.

Reporting Period
 
Valuation Technique
 
Significant Unobservable Inputs
 
Weighted Average Rates(a)
December 31, 2019
 
Discounted cash flow
 
Weighted average cost of capital
 
13.9
%
 
 
 
 
Adjusted EBITDA growth rate
 
28.1
%
 
 
 
 
 
 
 
June 30, 2019
 
Discounted cash flow
 
Weighted average cost of capital
 
14.2
%
 
 
 
 
Adjusted EBITDA growth rate
 
21.5
%

(a) Weighted average rates identified for each significant unobservable input relate to the valuation of the Intelisys contingent consideration.